{"gene":"THAP1","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":2005,"finding":"The THAP domain of THAP1 is a zinc-dependent sequence-specific DNA-binding domain. In vitro binding-site selection identified an 11-nucleotide consensus DNA-binding sequence. Mutations of single nucleotide positions in this sequence abrogated binding. The zinc chelator 1,10-o-phenanthroline abolished DNA binding, and site-directed mutagenesis of cysteine or histidine residues in the C2CH motif impaired zinc coordination and DNA binding. Four conserved residues (P, W, F, and P) were also required for DNA binding.","method":"In vitro binding-site selection, zinc chelation, site-directed mutagenesis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis and chelation experiments, multiple orthogonal methods in one study","pmids":["15863623"],"is_preprint":false},{"year":2003,"finding":"THAP1 is a nuclear proapoptotic factor that localizes to PML nuclear bodies and interacts with the proapoptotic protein Par-4. Endogenous Par-4 colocalizes with ectopic THAP1 within PML NBs in primary endothelial cells and fibroblasts. The THAP domain is not required for Par-4 binding or PML NB localization but is essential for THAP1 proapoptotic activity. THAP1 potentiates serum withdrawal- and TNF-alpha-induced apoptosis.","method":"Co-localization (immunofluorescence), domain deletion analysis, apoptosis assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-localization and functional domain deletion in primary cells, single lab with multiple methods","pmids":["12717420"],"is_preprint":false},{"year":2006,"finding":"THAP1 regulates endothelial cell proliferation and G1/S cell-cycle progression through coordinated repression of pRB/E2F cell-cycle target genes. Chromatin immunoprecipitation showed that endogenous THAP1 associates in vivo with a consensus THAP1-binding site in the RRM1 promoter, identifying RRM1 as a direct transcriptional target. Both overexpression and RNAi silencing of THAP1 inhibited EC proliferation and downregulated pRB/E2F target genes including RRM1.","method":"Retroviral gene transfer, microarray expression profiling, RNA interference, chromatin immunoprecipitation (ChIP)","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating direct promoter occupancy plus reciprocal gain- and loss-of-function with consistent phenotype, multiple orthogonal methods","pmids":["17003378"],"is_preprint":false},{"year":2007,"finding":"NMR structure-function analysis of the THAP zinc finger of THAP1 revealed it is an atypical zinc finger of ~80 residues with a short antiparallel beta-sheet interspersed by a loop-helix-loop insertion. Alanine scanning mutagenesis identified critical residues in the loop-helix-loop motif for DNA recognition. NMR chemical shift perturbation mapped the DNA-binding interface to a positively charged area harboring multiple lysine and arginine residues.","method":"Multidimensional NMR spectroscopy, deletion mutagenesis, alanine scanning mutagenesis, NMR chemical shift perturbation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — NMR structure determination combined with systematic mutagenesis and functional DNA-binding validation in one study","pmids":["18073205"],"is_preprint":false},{"year":2009,"finding":"A missense mutation in the THAP1 DNA-binding domain impairs DNA binding, as demonstrated by functional assay, establishing that transcriptional dysregulation via loss of THAP1 DNA-binding activity underlies DYT6 dystonia.","method":"Functional DNA-binding assay (electromobility shift or equivalent), mutation analysis","journal":"Nature genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay of DNA binding for disease mutation, single lab","pmids":["19182804"],"is_preprint":false},{"year":2010,"finding":"THAP1 associates with the transcriptional coactivator HCF-1 and O-GlcNAc transferase (OGT) in vivo. THAP1 interacts with HCF-1 through a consensus HCF-1-binding motif (HBM). ChIP assays showed that endogenous THAP1 mediates recruitment of HCF-1 to the RRM1 promoter during endothelial cell proliferation, and HCF-1 is required for transcriptional activation of RRM1.","method":"Proteomic analysis (mass spectrometry), in vitro binding assays, co-immunoprecipitation, chromatin immunoprecipitation (ChIP), RNA interference","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, MS-identified interaction, ChIP, and RNAi with functional readout; multiple orthogonal methods in one study","pmids":["20200153"],"is_preprint":false},{"year":2010,"finding":"THAP1 binds directly to the core promoter of TOR1A (DYT1) and represses its expression. Dystonia-associated mutant THAP1 shows decreased repression of TOR1A, as demonstrated by electromobility shift assays and ChIP-qPCR. Pathophysiologic mutations abolish the physical interaction between THAP1 and the TOR1A promoter.","method":"Electromobility shift assay (EMSA), chromatin immunoprecipitation (ChIP)-qPCR, luciferase reporter assays","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — EMSA and ChIP demonstrating direct promoter binding, replicated by independent group (PMID 20865765), multiple orthogonal methods","pmids":["20976771","20865765"],"is_preprint":false},{"year":2011,"finding":"THAP1 forms homodimers via its C-terminal coiled-coil domain. The interaction requires residues within a 13-amino-acid region (aa 154–166) containing leucine zipper-like elements. The DYT6 frameshift mutation Q154fs180X, which eliminates most of the coiled-coil domain, abolishes self-association, whereas other tested DYT6 mutations do not prevent dimerization.","method":"Co-immunoprecipitation, yeast two-hybrid (implied by domain mapping), deletion and truncation analysis","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP-based dimerization mapping with multiple deletion constructs, single lab","pmids":["21752024"],"is_preprint":false},{"year":2011,"finding":"A truncating THAP1 mutation (Asp191Thrfs*9) disrupts nuclear import, altering subcellular localization from nucleus to cytoplasm as shown by immunofluorescence microscopy of transfected cells.","method":"Immunofluorescence microscopy of transfected cells, luciferase reporter assay","journal":"European journal of human genetics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single co-localization experiment in transfected cells, single lab, limited functional follow-up","pmids":["21847143"],"is_preprint":false},{"year":2012,"finding":"NMR, fluorescence, DSF, and ITC analyses of DYT6 missense mutations in the THAP domain showed that none completely abolish DNA binding; some mutations even bind DNA more strongly than wild-type. However, several mutations decrease protein thermostability, with unfolding temperatures dropping from 46°C (wild-type) to below 37°C for mutations affecting zinc coordination, the hydrophobic core, or the C-terminal AVPTIF motif, suggesting that reduced population of folded protein under physiological conditions may account for disease.","method":"NMR spectroscopy, fluorescence spectroscopy, differential scanning fluorimetry (DSF), isothermal titration calorimetry (ITC)","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — four orthogonal biophysical methods applied to multiple mutations in one study, rigorous quantitative assessment","pmids":["22844099"],"is_preprint":false},{"year":2012,"finding":"Truncated THAP1 mutations (F22fs71X and F25fs53X) alter subcellular localization to both cytoplasm and nucleus, whereas missense mutations (C54F and L180S) remain predominantly nuclear, as shown by immunofluorescence and Western blot in transfected HEK-293T cells.","method":"Immunofluorescence microscopy, Western blot, transfection in HEK-293T cells","journal":"Parkinsonism & related disorders","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, overexpression in non-neuronal cell line, no functional consequence directly tested","pmids":["22652465"],"is_preprint":false},{"year":2014,"finding":"THAP1 autoregulates its own expression by binding to the THAP1 minimal promoter (a 480-bp fragment) and repressing transcription. This was demonstrated by luciferase reporter assays and quantitative ChIP. DYT6-causing mutations disrupt this autoregulation. Overexpressed THAP1 is preferentially degraded via the proteasome, and endogenous THAP1 levels are reduced in cells overexpressing wild-type THAP1.","method":"Luciferase reporter assay, quantitative ChIP, RT-qPCR, proteasome inhibitor treatment","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus reporter assay plus endogenous expression measurement, single lab with multiple orthogonal methods","pmids":["25088175"],"is_preprint":false},{"year":2014,"finding":"Endogenous THAP1 exists as multiple protein species (29–30 kDa, 32 kDa, 47 kDa, and 50–52 kDa) in neurons. The 50-kDa species is exclusively detected in murine brain and testes and is localized to the nuclear compartment, distinct from non-neuronal isoforms, suggesting neuron-specific post-translational modifications.","method":"Western blotting, immunoprecipitation, DNA oligonucleotide affinity chromatography, subcellular fractionation","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple antibodies validated by IP and affinity chromatography, in vivo tissue fractionation, single lab","pmids":["25231164"],"is_preprint":false},{"year":2017,"finding":"THAP1 is essential for timing the initiation of CNS myelination in a cell-autonomous manner within the oligodendrocyte (OL) lineage. Conditional deletion of THAP1 in the CNS retards OL maturation, delays myelination, and causes persistent motor deficits. Loss of THAP1 disrupts a core set of OL maturation genes and reduces DNA occupancy of YY1, a transcription factor required for OL maturation.","method":"Conditional knockout mouse (CNS-specific Cre), OL progenitor purification and developmental assays, ChIP, motor behavior testing","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO with defined cellular and behavioral phenotype, ChIP for mechanistic placement, in vitro OPC rescue, single lab with multiple orthogonal methods","pmids":["28697333"],"is_preprint":false},{"year":2017,"finding":"THAP1 regulates embryonic stem cell survival, proliferation, and neuroectodermal differentiation. Loss of THAP1 or expression of a disease-causing mutation enhances cell death, prolongs pluripotency gene expression (Nanog, Prdm14, Rex1) upon differentiation, and impairs upregulation of ectodermal genes. ChIP-Seq reveals that these activities are partly due to indirect regulation of gene expression.","method":"Knockout ESCs, disease-mutation knock-in ESCs, ChIP-Seq, differentiation assays, cell survival assays","journal":"Stem cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and KI in ESCs with ChIP-Seq, single lab with multiple methods","pmids":["28579396"],"is_preprint":false},{"year":2017,"finding":"The THAP1 homodimerization domain maps to amino acids 139–185 of the coiled-coil region. Yeast two-hybrid, GST pull-down, and cross-linking assays confirmed this region mediates homodimerization. Nine DYT6-causing missense mutations within this region had no effect on THAP1 dimerization.","method":"Yeast two-hybrid, GST pull-down, formaldehyde cross-linking assays","journal":"Journal of molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — three orthogonal protein-interaction methods in one study, single lab","pmids":["28299530"],"is_preprint":false},{"year":2018,"finding":"Heterozygous Thap1 C54Y or ΔExon2 alleles in mouse striatum and cerebellum dysregulate pathways including eIF2α signaling, mitochondrial dysfunction, neuron projection development, axonal guidance signaling, and synaptic long-term depression in a genotype- and tissue-dependent manner. There is a unique neuronal 50-kDa Thap1 immunoreactive species, and Thap1 levels are auto-regulated at the mRNA level. Electrophysiological and neurite outgrowth deficits consistent with pathway enrichments were partially corrected by salubrinal.","method":"RNA-Seq (in vivo), electrophysiology, neurite outgrowth assays, pharmacological rescue","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo RNA-Seq with functional electrophysiological and pharmacological validation, single lab","pmids":["29364887"],"is_preprint":false},{"year":2021,"finding":"THAP1, together with YY1 and HCF1, binds directly to the SHLD1 promoter and cooperatively maintains low basal expression of the Shieldin component SHLD1, thereby regulating the choice between end protection and resection during DNA double-strand break repair. Loss of THAP1-dependent SHLD1 expression confers cross-resistance to PARP inhibitors and cisplatin in BRCA1-deficient cells.","method":"ChIP, promoter reporter assays, PARP inhibitor sensitivity assays, genetic rescue experiments in BRCA1-deficient cells","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct ChIP of promoter binding, functional genetic rescue, multiple cell-line and mouse model validation, single lab with multiple orthogonal methods","pmids":["33857404"],"is_preprint":false},{"year":2021,"finding":"THAP1 modulates oligodendrocyte maturation by regulating lysosomal glycosaminoglycan (GAG) catabolism in OPCs. Thap1-null OPCs accumulate and secrete excess GAGs, inhibiting their maturation via an autoinhibitory mechanism. THAP1 binds to and regulates the GusB gene encoding β-glucuronidase. Applying GAG-degrading enzymes or overexpressing β-glucuronidase rescues Thap1-null OL maturation deficits in vitro and in vivo.","method":"Thap1 knockout OPCs, ChIP (GusB promoter binding), glycosaminoglycan quantification, rescue by GAG-degrading enzymes and GusB overexpression in vitro and in vivo","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating direct target gene binding, biochemical GAG measurement, and in vivo rescue experiment; multiple orthogonal methods, single lab","pmids":["34312226"],"is_preprint":false},{"year":2021,"finding":"Dystonia-specific THAP1 mutations dysregulate genes related to neurodevelopment, lysosomal lipid metabolism, and myelin in near-isogenic iPSC-derived neural stem cells. In vivo, Thap1-disruptive alleles in mice cause significant changes in myelin gene expression and reduction of myelin structural integrity.","method":"iPSC-derived neural stem cells (allelic series of 8 mutations), RNA-Seq, mouse myelin histology/gene expression","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — near-isogenic iPSC allelic series (n=94 lines) plus in vivo mouse confirmation, multiple mutations and methods","pmids":["34672987"],"is_preprint":false},{"year":2022,"finding":"The DYT6 missense mutation F81L (THAP1F81L) impairs THAP1 transcriptional activity and disrupts CNS myelination. THAP1F81L exhibits normal DNA binding but causes significantly reduced DNA binding of its transcriptional partner YY1 at target promoters, suggesting the mutation disrupts formation of an active transcription complex rather than direct DNA binding.","method":"Knock-in mouse model, ChIP (YY1 and THAP1 occupancy), myelination assays, transcriptional reporter assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — knock-in mouse with ChIP demonstrating mechanism (YY1 displacement), in vivo myelination phenotype, multiple methods in single study","pmids":["34686877"],"is_preprint":false},{"year":2022,"finding":"THAP1 regulates gene expression mainly through control of SP1 family members SP1 and SP4 in a cell-type-dependent manner. ChIP-seq showed THAP1 directly targets only a minority of differentially expressed genes; the majority are regulated indirectly via SP1/SP4. Common dysregulated genes across THAP1 patient neurons and knockout rat striatum involve synaptic transmission, nervous system development, and locomotor behavior pathways.","method":"ChIP-seq, RNA-seq, transcriptomic comparison across multiple model systems (patient iPSC-derived neurons, KO rat striatum, patient frontal cortex), electrophysiology, behavioral assays","journal":"Brain","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP-seq with multiple independent model systems and functional electrophysiological/behavioral validation","pmids":["35015830"],"is_preprint":false},{"year":2013,"finding":"Par-4 and THAP1 form a protein complex via interaction of their carboxyl termini, and this complex binds to the CCAR1 promoter through the zinc-dependent DNA-binding domain of THAP1 at its amino terminus. The Par-4/THAP1 complex and Notch3 competitively bind to the CCAR1 promoter and antagonistically regulate alternative pre-mRNA splicing of CCAR1 via splicing factors SRp40 and SRp55, determining T-ALL cell survival.","method":"Co-immunoprecipitation, luciferase reporter assay, ChIP, alternative splicing analysis","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of complex, ChIP of promoter binding, splicing assays; single lab with multiple orthogonal methods","pmids":["23975424"],"is_preprint":false},{"year":2020,"finding":"THAP1 directly binds the promoter of the SOD2 (superoxide dismutase 2) gene as shown by ChIP-seq, and overexpression of THAP1 in SK-N-AS cells increases SOD2 protein expression, whereas fibroblasts from THAP1 patients show reduced SOD2 expression. Disease mutations C54Y and F81L decrease THAP1 protein stability.","method":"ChIP-seq, microarray expression profiling, Western blot, patient fibroblast analysis","journal":"Journal of molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP-seq for direct binding plus gain- and loss-of-function expression data; single lab","pmids":["32112337"],"is_preprint":false},{"year":2025,"finding":"THAP1 directly regulates the expression of PSMB5, which encodes the central protease subunit β5 of the 26S proteasome. Depletion of THAP1 disrupts proteasome assembly, reduces proteasome activity, and leads to accumulation of ubiquitinated proteins and cell death. This was identified through a genome-wide genetic screen and confirmed by direct PSMB5 promoter binding and rescue experiments.","method":"Genome-wide genetic screen (DepMap coessentiality), THAP1 depletion, proteasome activity assays, ubiquitinated protein accumulation assay, PSMB5 promoter binding assays, RNA-seq, deep mutational scanning of THAP1","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — two independent publications (PMIDs 39952963 and 39929834) with genome-wide screen, direct promoter binding, proteasome assembly and activity assays, and deep mutational scan","pmids":["39952963","39929834"],"is_preprint":false},{"year":2026,"finding":"THAP1 functions as a maternal effect factor in mouse oocytes and early embryos. Oocyte-specific deletion of Thap1 causes 1-2-cell arrest, defective zygotic genome activation, and impaired female fertility. Mechanistically, THAP1 activates Rrm1 (ribonucleotide reductase) in oocytes to generate dNTPs; overexpression of Rrm1 in Thap1 maternal-KO zygotes nearly fully rescues 2-cell progression and ZGA.","method":"Oocyte-specific conditional knockout, low-input metabolomics, RNA-seq (ZGA assay), Rrm1 mRNA rescue by overexpression","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with direct genetic rescue by Rrm1 overexpression, metabolomics confirming dNTP depletion, multiple orthogonal methods in one study","pmids":["41731150"],"is_preprint":false},{"year":2021,"finding":"Loss of THAP1 in striatal medium spiny neurons derived from DYT-THAP1 patient iPSCs results in significantly lower GABA-evoked calcium amplitudes and marked downregulation of the GABA-A receptor alpha2 subunit gene, lower frequency of miniature postsynaptic currents, and elevated spontaneous action potential frequency, indicating decreased GABAergic transmission and neuronal disinhibition/hyperexcitability.","method":"iPSC-derived medium spiny neurons, calcium imaging, qPCR, whole-cell patch-clamp electrophysiology","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — patient iPSC-derived neurons with electrophysiology and molecular quantification, single lab","pmids":["34095114"],"is_preprint":false},{"year":2019,"finding":"Conditional deletion of Thap1 in neural/glial precursors (nestin-Cre) causes pronounced locomotor deficits with transcriptional changes in genes involved in nervous system development, synaptic transmission, cytoskeleton, gliosis, and dopamine signaling. Germline deletion of Thap1 is embryonic lethal. Heterozygous mice show autoregulation of Thap1 mRNA with compensatory upregulation from the intact allele.","method":"Conditional knockout mice (nestin-Cre), germline knockout, RNA-seq, behavioral testing","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo conditional KO with behavioral and transcriptomic phenotyping, single lab","pmids":["30590536"],"is_preprint":false}],"current_model":"THAP1 is a zinc-dependent, sequence-specific DNA-binding transcription factor (via its N-terminal THAP zinc finger domain) that recruits the coactivator HCF-1 and OGT to target promoters including RRM1, TOR1A, SOD2, PSMB5, and GusB; it represses TOR1A and its own promoter (autoregulation), activates RRM1 and PSMB5 (maintaining proteasome function), and in partnership with YY1 controls myelination by regulating OL lineage maturation through lysosomal GAG catabolism; THAP1 also interacts with Par-4 at PML nuclear bodies to promote apoptosis, homodimerizes via a leucine zipper-like coiled-coil (aa 154–166), and binds the SHLD1 promoter together with YY1 and HCF1 to balance DNA double-strand break repair pathway choice, with DYT6-causing mutations impairing DNA binding, protein stability, autoregulation, YY1 co-recruitment, or nuclear localization."},"narrative":{"mechanistic_narrative":"THAP1 is a zinc-dependent, sequence-specific DNA-binding transcription factor that controls cell proliferation, differentiation, and survival through direct occupancy of defined promoter elements [PMID:15863623, PMID:17003378]. DNA recognition is mediated by an N-terminal atypical THAP zinc finger of ~80 residues that folds as an antiparallel beta-sheet with a loop-helix-loop insertion contacting an 11-nucleotide consensus, and that requires both zinc coordination through its C2CH motif and a positively charged lysine/arginine surface [PMID:15863623, PMID:18073205]. THAP1 acts within multiprotein transcriptional complexes: it recruits the coactivator HCF-1 (and associated OGT) to the RRM1 promoter to drive pRB/E2F-dependent cell-cycle gene expression and endothelial proliferation [PMID:17003378, PMID:20200153], represses the dystonia gene TOR1A and autoregulates its own promoter [PMID:20976771, PMID:20865765, PMID:25088175], and activates SOD2 and the proteasome subunit gene PSMB5 — the latter sustaining proteasome assembly and clearance of ubiquitinated proteins [PMID:32112337, PMID:39952963, PMID:39929834]. Much of its transcriptional output is indirect, channeled through control of the SP1/SP4 family in a cell-type-dependent manner [PMID:35015830]. In the oligodendrocyte lineage THAP1 partners with YY1 to time CNS myelination cell-autonomously, in part by regulating lysosomal glycosaminoglycan catabolism via the β-glucuronidase gene GusB [PMID:28697333, PMID:34312226, PMID:34686877]. THAP1 also balances DNA double-strand break repair pathway choice by binding the SHLD1 promoter together with YY1 and HCF1 to restrain Shieldin expression [PMID:33857404], drives apoptosis through interaction with Par-4 at PML nuclear bodies and at the CCAR1 promoter [PMID:12717420, PMID:23975424], and acts as a maternal-effect factor activating Rrm1 to supply dNTPs for zygotic genome activation [PMID:41731150]. The protein homodimerizes through a C-terminal coiled-coil region (aa 139–185) [PMID:21752024, PMID:28299530]. Dominant DYT6 dystonia is caused by THAP1 mutations that act through heterogeneous mechanisms — impaired DNA binding, reduced protein thermostability, loss of autoregulation, disrupted YY1 co-recruitment, or defective nuclear import — converging on transcriptional dysregulation [PMID:19182804, PMID:22844099, PMID:25088175, PMID:34686877].","teleology":[{"year":2003,"claim":"Established THAP1's first cellular role by showing it is a nuclear proapoptotic factor, placing it in PML nuclear bodies and physically linked to Par-4 before any DNA-binding function was known.","evidence":"Co-localization, domain-deletion analysis, and apoptosis assays in primary endothelial cells and fibroblasts","pmids":["12717420"],"confidence":"Medium","gaps":["Did not identify direct transcriptional targets","THAP domain shown dispensable for Par-4 binding but required for apoptosis without mechanism","Single lab co-localization"]},{"year":2005,"claim":"Defined the molecular activity of THAP1 by demonstrating the THAP domain is a zinc-dependent sequence-specific DNA-binding module with an 11-nucleotide consensus, converting an apoptosis factor into a candidate transcription factor.","evidence":"In vitro binding-site selection, zinc chelation, and site-directed mutagenesis","pmids":["15863623"],"confidence":"High","gaps":["No in vivo target gene identified","No structural model of domain","Did not address transcriptional activation versus repression"]},{"year":2006,"claim":"Connected DNA binding to physiological output by identifying RRM1 as a direct in vivo target and placing THAP1 in pRB/E2F-dependent control of G1/S progression and endothelial proliferation.","evidence":"ChIP for promoter occupancy plus reciprocal overexpression and RNAi with proliferation readout","pmids":["17003378"],"confidence":"High","gaps":["Did not identify coactivators recruited","Mechanism of pRB/E2F target regulation indirect","Restricted to endothelial cells"]},{"year":2007,"claim":"Resolved how THAP1 recognizes DNA by determining the NMR structure of the atypical zinc finger and mapping the loop-helix-loop DNA-binding interface.","evidence":"Multidimensional NMR, alanine scanning, and chemical shift perturbation","pmids":["18073205"],"confidence":"High","gaps":["No co-structure with DNA","C-terminal coiled-coil not structurally characterized","Did not address full-length protein behavior"]},{"year":2009,"claim":"Provided the first disease mechanism by showing a DYT6 missense mutation in the DNA-binding domain abolishes DNA binding, framing dystonia as transcriptional dysregulation.","evidence":"Functional DNA-binding assay of a disease mutation","pmids":["19182804"],"confidence":"Medium","gaps":["Single mutation tested","Did not establish which target genes are affected","No in vivo confirmation"]},{"year":2010,"claim":"Identified the coactivator machinery THAP1 uses and a key repressed target, showing THAP1 recruits HCF-1/OGT to activate RRM1 and directly represses the dystonia gene TOR1A.","evidence":"Mass spectrometry, reciprocal co-IP, ChIP, and RNAi (HCF-1/OGT); EMSA, ChIP-qPCR, and luciferase reporters (TOR1A), with independent replication","pmids":["20200153","20976771","20865765"],"confidence":"High","gaps":["How activation versus repression is determined at different promoters unresolved","OGT functional contribution not dissected","Link between TOR1A repression and dystonia phenotype not tested in vivo"]},{"year":2011,"claim":"Showed THAP1 homodimerizes through a C-terminal coiled-coil, and that a frameshift removing this region abolishes self-association while subcellular mislocalization defines another mutation class.","evidence":"Co-IP and deletion mapping (dimerization); immunofluorescence of transfected cells (mislocalization)","pmids":["21752024","21847143"],"confidence":"Medium","gaps":["Functional consequence of dimerization for transcription not established","Mislocalization shown in overexpression only","Most DYT6 mutations do not affect dimerization, leaving their mechanism open"]},{"year":2012,"claim":"Reframed DYT6 pathogenesis by showing most THAP-domain missense mutations do not abolish DNA binding but instead destabilize the folded protein below physiological temperature.","evidence":"NMR, fluorescence, differential scanning fluorimetry, and ITC across multiple mutations; immunofluorescence localization of truncations","pmids":["22844099","22652465"],"confidence":"High","gaps":["Thermostability measured in vitro, not in cells","Did not test whether destabilized protein is degraded in vivo","Localization data from overexpression in non-neuronal cells"]},{"year":2013,"claim":"Extended the Par-4 partnership into transcriptional and splicing control, showing the Par-4/THAP1 complex binds the CCAR1 promoter and antagonizes Notch3 to govern alternative splicing and T-ALL survival.","evidence":"Co-IP, ChIP, luciferase reporter, and splicing analysis","pmids":["23975424"],"confidence":"Medium","gaps":["Splicing regulation mechanism via SRp40/SRp55 not fully resolved","Single cancer-cell context","Relationship to canonical THAP1 transcriptional targets unclear"]},{"year":2014,"claim":"Established negative autoregulation and protein turnover as control mechanisms, showing THAP1 represses its own promoter, is degraded by the proteasome, and exists as neuron-specific protein species.","evidence":"Luciferase reporters, quantitative ChIP, RT-qPCR, and proteasome inhibition; Western blot, IP, and subcellular fractionation across tissues","pmids":["25088175","25231164"],"confidence":"Medium","gaps":["Identity of neuron-specific post-translational modifications unknown","Ubiquitin ligase mediating degradation not identified","Functional role of distinct isoforms untested"]},{"year":2017,"claim":"Defined THAP1's developmental functions in vivo, showing it is required cell-autonomously for oligodendrocyte maturation and myelination timing via YY1, and for embryonic stem cell survival and neuroectodermal differentiation.","evidence":"Conditional knockout mice with OL purification and ChIP (myelination); knockout/knock-in ESCs with ChIP-Seq (differentiation)","pmids":["28697333","28579396"],"confidence":"High","gaps":["Direct versus indirect target genes not fully separated","Mechanism of YY1 co-occupancy unresolved at this stage","Link to dystonia phenotype not yet established"]},{"year":2018,"claim":"Linked THAP1 dysfunction to specific neuronal pathways in vivo, showing heterozygous dystonia alleles dysregulate eIF2α signaling and synaptic pathways with electrophysiological deficits partially rescued pharmacologically.","evidence":"In vivo RNA-Seq of mouse striatum/cerebellum, electrophysiology, neurite outgrowth, and salubrinal rescue","pmids":["29364887"],"confidence":"Medium","gaps":["Direct THAP1 targets among dysregulated genes not defined","Tissue- and genotype-dependent effects mechanistically unexplained","salubrinal rescue only partial"]},{"year":2020,"claim":"Added oxidative-stress defense to THAP1's regulon by showing direct SOD2 promoter binding with dose-dependent expression control, and reinforced that disease mutations reduce protein stability.","evidence":"ChIP-seq, expression profiling, Western blot, and patient fibroblast analysis","pmids":["32112337"],"confidence":"Medium","gaps":["Physiological consequence of altered SOD2 not tested","Single lab","Cofactor requirements at SOD2 promoter unknown"]},{"year":2021,"claim":"Diversified THAP1's mechanistic repertoire across DNA repair, myelination metabolism, neuronal excitability, and SP1/SP4-mediated gene control, while resolving that most THAP1 transcriptional output is indirect.","evidence":"ChIP and PARP-inhibitor genetics (SHLD1); knockout OPCs with ChIP and GAG/GusB rescue; patient iPSC neurons with patch-clamp; iPSC allelic series with RNA-Seq and mouse myelin histology; ChIP-seq/RNA-seq across multiple models (SP1/SP4)","pmids":["33857404","34312226","34672987","34095114","35015830"],"confidence":"High","gaps":["How a single factor selects among repair, metabolic, and neuronal programs unclear","Determinants of direct versus SP1/SP4-indirect regulation undefined","Causal chain from transcriptional changes to dystonia behavior incomplete"]},{"year":2022,"claim":"Defined a transcription-complex-assembly mechanism for disease by showing the DYT6 F81L mutant binds DNA normally yet fails to co-recruit YY1, disrupting myelination.","evidence":"Knock-in mouse with ChIP for THAP1 and YY1 occupancy, myelination and reporter assays","pmids":["34686877"],"confidence":"High","gaps":["Structural basis of THAP1–YY1 cooperativity unknown","Whether other DYT6 mutations share this mechanism not tested here","Direct biochemical THAP1–YY1 interaction not demonstrated"]},{"year":2025,"claim":"Revealed an essential proteostasis function, showing THAP1 directly drives PSMB5 expression to sustain proteasome assembly and prevent toxic ubiquitinated-protein accumulation.","evidence":"Genome-wide coessentiality screen, depletion with proteasome activity assays, PSMB5 promoter binding, and deep mutational scanning, across two independent reports","pmids":["39952963","39929834"],"confidence":"High","gaps":["Tissue specificity of proteasome dependence unexplored","Relationship between proteasome control and dystonia phenotypes unknown","Cofactors at PSMB5 promoter not defined"]},{"year":2026,"claim":"Identified a maternal-effect role, showing oocyte THAP1 activates Rrm1 to supply dNTPs required for zygotic genome activation and early embryonic progression.","evidence":"Oocyte-specific conditional knockout, low-input metabolomics, RNA-seq, and Rrm1 mRNA rescue","pmids":["41731150"],"confidence":"High","gaps":["Whether RRM1 control is conserved in somatic THAP1 functions not addressed","Other maternal targets not mapped","Link to human reproductive phenotypes unknown"]},{"year":null,"claim":"How THAP1 selects among its diverse promoter targets and decides between activation and repression, direct versus SP1/SP4-mediated control, and which cofactor (HCF-1, YY1, Par-4, OGT) is engaged in a given cellular context remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unifying model linking context to cofactor choice","Causal chain from specific transcriptional changes to DYT6 dystonia incomplete","Genome-wide direct binding versus functional output discordance unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,3,6,17,18,23,24]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,5,6,11,21,24]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,8,10,12]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[1,2,5]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,5,6,11,21]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[2,25]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[17]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[13,14,18,20]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[24]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[1,22]}],"complexes":[],"partners":["HCF1","OGT","YY1","PAWR","SP1","SP4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9NVV9","full_name":"THAP domain-containing protein 1","aliases":[],"length_aa":213,"mass_kda":24.9,"function":"DNA-binding transcription regulator that regulates endothelial cell proliferation and G1/S cell-cycle progression. Specifically binds the 5'-[AT]NTNN[GT]GGCA[AGT]-3' core DNA sequence and acts by modulating expression of pRB-E2F cell-cycle target genes, including RRM1. Component of a THAP1/THAP3-HCFC1-OGT complex that is required for the regulation of the transcriptional activity of RRM1. May also have pro-apoptotic activity by potentiating both serum-withdrawal and TNF-induced apoptosis","subcellular_location":"Nucleus, nucleoplasm; Nucleus, PML body","url":"https://www.uniprot.org/uniprotkb/Q9NVV9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/THAP1","classification":"Common Essential","n_dependent_lines":1068,"n_total_lines":1208,"dependency_fraction":0.8841059602649006},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/THAP1","total_profiled":1310},"omim":[{"mim_id":"617284","title":"DYSTONIA 28, CHILDHOOD-ONSET; DYT28","url":"https://www.omim.org/entry/617284"},{"mim_id":"612532","title":"THAP DOMAIN-CONTAINING PROTEIN 3; THAP3","url":"https://www.omim.org/entry/612532"},{"mim_id":"612531","title":"THAP DOMAIN-CONTAINING PROTEIN 2; THAP2","url":"https://www.omim.org/entry/612531"},{"mim_id":"609520","title":"THAP DOMAIN-CONTAINING PROTEIN 1; THAP1","url":"https://www.omim.org/entry/609520"},{"mim_id":"606834","title":"LYSINE-SPECIFIC METHYLTRANSFERASE 2B; KMT2B","url":"https://www.omim.org/entry/606834"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/THAP1"},"hgnc":{"alias_symbol":["FLJ10477","4833431A01Rik"],"prev_symbol":["DYT6"]},"alphafold":{"accession":"Q9NVV9","domains":[{"cath_id":"-","chopping":"1-82","consensus_level":"medium","plddt":78.2461,"start":1,"end":82},{"cath_id":"1.20.5","chopping":"139-200","consensus_level":"high","plddt":86.0952,"start":139,"end":200}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NVV9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NVV9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9NVV9-F1-predicted_aligned_error_v6.png","plddt_mean":70.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=THAP1","jax_strain_url":"https://www.jax.org/strain/search?query=THAP1"},"sequence":{"accession":"Q9NVV9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9NVV9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9NVV9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9NVV9"}},"corpus_meta":[{"pmid":"19182804","id":"PMC_19182804","title":"Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19182804","citation_count":244,"is_preprint":false},{"pmid":"19345147","id":"PMC_19345147","title":"Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study.","date":"2009","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19345147","citation_count":130,"is_preprint":false},{"pmid":"15863623","id":"PMC_15863623","title":"The THAP domain of THAP1 is a large C2CH module with zinc-dependent sequence-specific DNA-binding activity.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15863623","citation_count":126,"is_preprint":false},{"pmid":"12717420","id":"PMC_12717420","title":"THAP1 is a nuclear proapoptotic factor that links prostate-apoptosis-response-4 (Par-4) to PML nuclear bodies.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12717420","citation_count":124,"is_preprint":false},{"pmid":"17003378","id":"PMC_17003378","title":"The THAP-zinc finger protein THAP1 regulates endothelial cell proliferation through modulation of pRB/E2F cell-cycle target genes.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17003378","citation_count":117,"is_preprint":false},{"pmid":"19345148","id":"PMC_19345148","title":"Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic dysphonia: a genetic screening study.","date":"2009","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19345148","citation_count":116,"is_preprint":false},{"pmid":"20200153","id":"PMC_20200153","title":"The THAP-zinc finger protein THAP1 associates with coactivator HCF-1 and O-GlcNAc transferase: a link between DYT6 and DYT3 dystonias.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20200153","citation_count":91,"is_preprint":false},{"pmid":"20083799","id":"PMC_20083799","title":"Novel THAP1 sequence variants in primary dystonia.","date":"2010","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20083799","citation_count":83,"is_preprint":false},{"pmid":"20211909","id":"PMC_20211909","title":"THAP1 mutations (DYT6) are an additional cause of early-onset dystonia.","date":"2010","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20211909","citation_count":82,"is_preprint":false},{"pmid":"20687191","id":"PMC_20687191","title":"DYT6 dystonia: mutation screening, phenotype, and response to deep brain stimulation.","date":"2010","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/20687191","citation_count":76,"is_preprint":false},{"pmid":"20976771","id":"PMC_20976771","title":"The dystonia gene DYT1 is repressed by the transcription factor THAP1 (DYT6).","date":"2010","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20976771","citation_count":75,"is_preprint":false},{"pmid":"22377579","id":"PMC_22377579","title":"Genotype-phenotype correlations in THAP1 dystonia: molecular foundations and description of new cases.","date":"2012","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22377579","citation_count":72,"is_preprint":false},{"pmid":"18073205","id":"PMC_18073205","title":"Structure-function analysis of the THAP zinc finger of THAP1, a large C2CH DNA-binding module linked to Rb/E2F pathways.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18073205","citation_count":68,"is_preprint":false},{"pmid":"21949105","id":"PMC_21949105","title":"Pallidal deep brain stimulation for DYT6 dystonia.","date":"2011","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21949105","citation_count":66,"is_preprint":false},{"pmid":"20865765","id":"PMC_20865765","title":"Direct interaction between causative genes of DYT1 and DYT6 primary dystonia.","date":"2010","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20865765","citation_count":66,"is_preprint":false},{"pmid":"29364887","id":"PMC_29364887","title":"Mutations in THAP1/DYT6 reveal that diverse dystonia genes disrupt similar neuronal pathways and functions.","date":"2018","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29364887","citation_count":63,"is_preprint":false},{"pmid":"24135862","id":"PMC_24135862","title":"SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia.","date":"2013","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/24135862","citation_count":60,"is_preprint":false},{"pmid":"17702011","id":"PMC_17702011","title":"Narrowing the DYT6 dystonia region and evidence for locus heterogeneity in the Amish-Mennonites.","date":"2007","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/17702011","citation_count":54,"is_preprint":false},{"pmid":"22903657","id":"PMC_22903657","title":"THAP1 mutations and dystonia phenotypes: genotype phenotype correlations.","date":"2012","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/22903657","citation_count":53,"is_preprint":false},{"pmid":"21793105","id":"PMC_21793105","title":"DYT6 dystonia: review of the literature and creation of the UMD Locus-Specific Database (LSDB) for mutations in the THAP1 gene.","date":"2011","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/21793105","citation_count":50,"is_preprint":false},{"pmid":"28697333","id":"PMC_28697333","title":"The DYT6 Dystonia Protein THAP1 Regulates Myelination within the Oligodendrocyte Lineage.","date":"2017","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/28697333","citation_count":49,"is_preprint":false},{"pmid":"26376866","id":"PMC_26376866","title":"Abnormalities of motor function, transcription and cerebellar structure in mouse models of THAP1 dystonia.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26376866","citation_count":47,"is_preprint":false},{"pmid":"21847143","id":"PMC_21847143","title":"Identification and functional analysis of novel THAP1 mutations.","date":"2011","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/21847143","citation_count":42,"is_preprint":false},{"pmid":"19908325","id":"PMC_19908325","title":"Mutation screening of the DYT6/THAP1 gene in Italy.","date":"2009","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/19908325","citation_count":37,"is_preprint":false},{"pmid":"20687193","id":"PMC_20687193","title":"Clinical neuroimaging and electrophysiological assessment of three DYT6 dystonia families.","date":"2010","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/20687193","citation_count":35,"is_preprint":false},{"pmid":"21425335","id":"PMC_21425335","title":"Homozygous THAP1 mutations as cause of early-onset generalized dystonia.","date":"2011","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/21425335","citation_count":33,"is_preprint":false},{"pmid":"28579396","id":"PMC_28579396","title":"THAP1: Role in Mouse Embryonic Stem Cell Survival and Differentiation.","date":"2017","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/28579396","citation_count":32,"is_preprint":false},{"pmid":"23975424","id":"PMC_23975424","title":"Par-4/THAP1 complex and Notch3 competitively regulated pre-mRNA splicing of CCAR1 and affected inversely the survival of T-cell acute lymphoblastic leukemia cells.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/23975424","citation_count":31,"is_preprint":false},{"pmid":"20825472","id":"PMC_20825472","title":"Clinical and genetic evaluation of DYT1 and DYT6 primary dystonia in China.","date":"2010","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/20825472","citation_count":30,"is_preprint":false},{"pmid":"30590536","id":"PMC_30590536","title":"Loss of the dystonia gene Thap1 leads to transcriptional deficits that converge on common pathogenic pathways in dystonic syndromes.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30590536","citation_count":30,"is_preprint":false},{"pmid":"24500857","id":"PMC_24500857","title":"Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites.","date":"2014","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/24500857","citation_count":30,"is_preprint":false},{"pmid":"26486352","id":"PMC_26486352","title":"Long-term effect on dystonia after pallidal deep brain stimulation (DBS) in three members of a family with a THAP1 mutation.","date":"2015","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26486352","citation_count":30,"is_preprint":false},{"pmid":"20669277","id":"PMC_20669277","title":"Prevalence of THAP1 sequence variants in German patients with primary dystonia.","date":"2010","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/20669277","citation_count":29,"is_preprint":false},{"pmid":"25359437","id":"PMC_25359437","title":"Deep brain stimulation of the thalamic ventral lateral anterior nucleus for DYT6 dystonia.","date":"2014","source":"Stereotactic and functional neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/25359437","citation_count":29,"is_preprint":false},{"pmid":"21752024","id":"PMC_21752024","title":"Dimerization of the DYT6 dystonia protein, THAP1, requires residues within the coiled-coil domain.","date":"2011","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21752024","citation_count":26,"is_preprint":false},{"pmid":"33857404","id":"PMC_33857404","title":"The dystonia gene THAP1 controls DNA double-strand break repair choice.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/33857404","citation_count":24,"is_preprint":false},{"pmid":"22844099","id":"PMC_22844099","title":"Towards the classification of DYT6 dystonia mutants in the DNA-binding domain of THAP1.","date":"2012","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/22844099","citation_count":21,"is_preprint":false},{"pmid":"23219941","id":"PMC_23219941","title":"Neural expression of the transcription factor THAP1 during development in rat.","date":"2012","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23219941","citation_count":21,"is_preprint":false},{"pmid":"34672987","id":"PMC_34672987","title":"Dystonia-specific mutations in THAP1 alter transcription of genes associated with neurodevelopment and myelin.","date":"2021","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34672987","citation_count":21,"is_preprint":false},{"pmid":"25088175","id":"PMC_25088175","title":"THAP1, the gene mutated in DYT6 dystonia, autoregulates its own expression.","date":"2014","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/25088175","citation_count":20,"is_preprint":false},{"pmid":"26610312","id":"PMC_26610312","title":"DYT6 Dystonia: A Neuropathological Study.","date":"2015","source":"Neuro-degenerative diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26610312","citation_count":18,"is_preprint":false},{"pmid":"24862462","id":"PMC_24862462","title":"Combined occurrence of a novel TOR1A and a THAP1 mutation in primary dystonia.","date":"2014","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/24862462","citation_count":18,"is_preprint":false},{"pmid":"31158945","id":"PMC_31158945","title":"The Effect of Globus Pallidus Interna Deep Brain Stimulation on a Dystonia Patient with the GNAL Mutation Compared to Patients with DYT1 and DYT6.","date":"2019","source":"Journal of movement disorders","url":"https://pubmed.ncbi.nlm.nih.gov/31158945","citation_count":18,"is_preprint":false},{"pmid":"21370264","id":"PMC_21370264","title":"The c.-237_236GA>TT THAP1 sequence variant does not increase risk for primary dystonia.","date":"2011","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/21370264","citation_count":18,"is_preprint":false},{"pmid":"20925076","id":"PMC_20925076","title":"Screening of Brazilian families with primary dystonia reveals a novel THAP1 mutation and a de novo TOR1A GAG deletion.","date":"2010","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/20925076","citation_count":18,"is_preprint":false},{"pmid":"21800139","id":"PMC_21800139","title":"THAP1/DYT6 sequence variants in non-DYT1 early-onset primary dystonia in China and their effects on RNA expression.","date":"2011","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21800139","citation_count":17,"is_preprint":false},{"pmid":"24936516","id":"PMC_24936516","title":"A rare sequence variant in intron 1 of THAP1 is associated with primary dystonia.","date":"2014","source":"Molecular genetics & genomic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24936516","citation_count":17,"is_preprint":false},{"pmid":"22652465","id":"PMC_22652465","title":"Subcellular distribution of THAP1 and alterations in the microstructure of brain white matter in DYT6 dystonia.","date":"2012","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/22652465","citation_count":16,"is_preprint":false},{"pmid":"32112337","id":"PMC_32112337","title":"Unraveling Molecular Mechanisms of THAP1 Missense Mutations in DYT6 Dystonia.","date":"2020","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/32112337","citation_count":15,"is_preprint":false},{"pmid":"33547842","id":"PMC_33547842","title":"Linking Penetrance and Transcription in DYT-THAP1: Insights From a Human iPSC-Derived Cortical Model.","date":"2021","source":"Movement disorders : official journal of the Movement Disorder Society","url":"https://pubmed.ncbi.nlm.nih.gov/33547842","citation_count":15,"is_preprint":false},{"pmid":"34312226","id":"PMC_34312226","title":"THAP1 modulates oligodendrocyte maturation by regulating ECM degradation in lysosomes.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34312226","citation_count":15,"is_preprint":false},{"pmid":"23180184","id":"PMC_23180184","title":"Mutation screening of the DYT6/THAP1 gene in Serbian patients with primary dystonia.","date":"2012","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23180184","citation_count":13,"is_preprint":false},{"pmid":"34686877","id":"PMC_34686877","title":"A pathogenic DYT-THAP1 dystonia mutation causes hypomyelination and loss of YY1 binding.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34686877","citation_count":12,"is_preprint":false},{"pmid":"27913194","id":"PMC_27913194","title":"Genetic screening of THAP1 in primary dystonia patients of India.","date":"2016","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/27913194","citation_count":12,"is_preprint":false},{"pmid":"34095114","id":"PMC_34095114","title":"Reduced Expression of GABA  Receptor Alpha2 Subunit Is Associated With Disinhibition of DYT-THAP1 Dystonia Patient-Derived Striatal Medium Spiny Neurons.","date":"2021","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34095114","citation_count":12,"is_preprint":false},{"pmid":"31133547","id":"PMC_31133547","title":"Intracranial calcifications and dystonia associated with a novel deletion of chromosome 8p11.2 encompassing SLC20A2 and THAP1.","date":"2019","source":"BMJ case reports","url":"https://pubmed.ncbi.nlm.nih.gov/31133547","citation_count":11,"is_preprint":false},{"pmid":"35015830","id":"PMC_35015830","title":"DYT6 mutated THAP1 is a cell type dependent regulator of the SP1 family.","date":"2022","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35015830","citation_count":10,"is_preprint":false},{"pmid":"25231164","id":"PMC_25231164","title":"Dystonia type 6 gene product Thap1: identification of a 50 kDa DNA-binding species in neuronal nuclear fractions.","date":"2014","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/25231164","citation_count":10,"is_preprint":false},{"pmid":"21839475","id":"PMC_21839475","title":"Novel THAP1 gene mutations in patients with primary dystonia from southwest China.","date":"2011","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21839475","citation_count":10,"is_preprint":false},{"pmid":"28299530","id":"PMC_28299530","title":"In-depth Characterization of the Homodimerization Domain of the Transcription Factor THAP1 and Dystonia-Causing Mutations Therein.","date":"2017","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/28299530","citation_count":10,"is_preprint":false},{"pmid":"24976531","id":"PMC_24976531","title":"Novel THAP1 variants in Brazilian patients with idiopathic isolated dystonia.","date":"2014","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24976531","citation_count":10,"is_preprint":false},{"pmid":"25385508","id":"PMC_25385508","title":"High variability of clinical symptoms in a Polish family with a novel THAP1 mutation.","date":"2014","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25385508","citation_count":8,"is_preprint":false},{"pmid":"39952963","id":"PMC_39952963","title":"The DYT6 dystonia causative protein THAP1 is responsible for proteasome activity via PSMB5 transcriptional regulation.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39952963","citation_count":7,"is_preprint":false},{"pmid":"24757586","id":"PMC_24757586","title":"DYT6 in Brazil: Genetic Assessment and Clinical Characteristics of Patients.","date":"2014","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/24757586","citation_count":7,"is_preprint":false},{"pmid":"39929834","id":"PMC_39929834","title":"Loss-of-function mutations in the dystonia gene THAP1 impair proteasome function by inhibiting PSMB5 expression.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39929834","citation_count":6,"is_preprint":false},{"pmid":"23439738","id":"PMC_23439738","title":"Spatial Discrimination Threshold Abnormalities are not Detected in a Pilot Study of DYT6 Dystonia Mutation Carriers.","date":"2012","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23439738","citation_count":6,"is_preprint":false},{"pmid":"30316041","id":"PMC_30316041","title":"Generation and characterization of eight human-derived iPSC lines from affected and unaffected THAP1 mutation carriers.","date":"2018","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30316041","citation_count":4,"is_preprint":false},{"pmid":"33175450","id":"PMC_33175450","title":"Mutational spectrum of GNAL, THAP1 and TOR1A genes in isolated dystonia: study in a population from Spain and systematic literature review.","date":"2020","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33175450","citation_count":3,"is_preprint":false},{"pmid":"31367947","id":"PMC_31367947","title":"Cerebellar Involvement in DYT-THAP1 Dystonia.","date":"2019","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31367947","citation_count":3,"is_preprint":false},{"pmid":"36096774","id":"PMC_36096774","title":"A case of novel DYT6 dystonia variant with serious complications after deep brain stimulation therapy: a case report.","date":"2022","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/36096774","citation_count":3,"is_preprint":false},{"pmid":"38835919","id":"PMC_38835919","title":"Emerging role of a systems biology approach to elucidate factors of reduced penetrance: transcriptional changes in THAP1-linked dystonia as an example.","date":"2022","source":"Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V","url":"https://pubmed.ncbi.nlm.nih.gov/38835919","citation_count":3,"is_preprint":false},{"pmid":"39732371","id":"PMC_39732371","title":"Peripheral nerve injury induces dystonia-like movements and dysregulation in the energy metabolism: A multi-omics descriptive study in Thap1+/- mice.","date":"2024","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/39732371","citation_count":3,"is_preprint":false},{"pmid":"26940431","id":"PMC_26940431","title":"New THAP1 mutation and role of putative modifier in TOR1A.","date":"2016","source":"Acta neurologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/26940431","citation_count":2,"is_preprint":false},{"pmid":"34802187","id":"PMC_34802187","title":"Pharmacological perturbation reveals deficits in D2 receptor responses in Thap1 null mice.","date":"2021","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34802187","citation_count":2,"is_preprint":false},{"pmid":"39180203","id":"PMC_39180203","title":"MS4A3 Promotes the Chemosensitivity of Lung Cancer via THAP1/EGFR Pathways.","date":"2024","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/39180203","citation_count":2,"is_preprint":false},{"pmid":"26803725","id":"PMC_26803725","title":"Lack of association between TOR1A and THAP1 mutations and sporadic adult-onset primary focal dystonia in a Chinese population.","date":"2016","source":"Clinical neurology and neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/26803725","citation_count":2,"is_preprint":false},{"pmid":"26087139","id":"PMC_26087139","title":"Screening for THAP1 Mutations in Polish Patients with Dystonia Shows Known and Novel Substitutions.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26087139","citation_count":2,"is_preprint":false},{"pmid":"38737544","id":"PMC_38737544","title":"Transcriptional regulatory network for neuron-glia interactions and its implication for DYT6 dystonia.","date":"2023","source":"Dystonia (Lausanne, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38737544","citation_count":1,"is_preprint":false},{"pmid":"25168324","id":"PMC_25168324","title":"Intrafamilial variability of the primary dystonia DYT6 phenotype caused by p.Cys5Trp mutation in THAP1 gene.","date":"2014","source":"Neurologia i neurochirurgia polska","url":"https://pubmed.ncbi.nlm.nih.gov/25168324","citation_count":1,"is_preprint":false},{"pmid":"40735195","id":"PMC_40735195","title":"Case report: Lingual dystonia symptoms treated with botulinum toxin in patients with THAP1 mutation.","date":"2024","source":"Dystonia (Lausanne, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/40735195","citation_count":1,"is_preprint":false},{"pmid":"34998426","id":"PMC_34998426","title":"Changes in pallidal neural activity following long-term symptom improvement from botulinum toxin treatment in DYT6 dystonia: a case report.","date":"2022","source":"Journal of medical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/34998426","citation_count":1,"is_preprint":false},{"pmid":"37637848","id":"PMC_37637848","title":"Generalized Dystonia Due to a Pathogenic THAP1 Variant Showing Sustained Response to Globus Pallidus Deep Brain Stimulation.","date":"2023","source":"Tremor and other hyperkinetic movements (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37637848","citation_count":1,"is_preprint":false},{"pmid":"41731150","id":"PMC_41731150","title":"THAP1 is a maternal effect factor required for the first cell cycle via Rrm1 in early mouse embryos.","date":"2026","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/41731150","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.12.02.24316741","title":"Genetic Diversity and Expanded Phenotypes in Dystonia: Insights from Large-Scale Exome Sequencing","date":"2024-12-05","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.02.24316741","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41086,"output_tokens":7293,"usd":0.116326,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":16540,"output_tokens":5766,"usd":0.113425,"stage2_stop_reason":"end_turn"},"total_usd":0.229751,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2005,\n      \"finding\": \"The THAP domain of THAP1 is a zinc-dependent sequence-specific DNA-binding domain. In vitro binding-site selection identified an 11-nucleotide consensus DNA-binding sequence. Mutations of single nucleotide positions in this sequence abrogated binding. The zinc chelator 1,10-o-phenanthroline abolished DNA binding, and site-directed mutagenesis of cysteine or histidine residues in the C2CH motif impaired zinc coordination and DNA binding. Four conserved residues (P, W, F, and P) were also required for DNA binding.\",\n      \"method\": \"In vitro binding-site selection, zinc chelation, site-directed mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis and chelation experiments, multiple orthogonal methods in one study\",\n      \"pmids\": [\"15863623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"THAP1 is a nuclear proapoptotic factor that localizes to PML nuclear bodies and interacts with the proapoptotic protein Par-4. Endogenous Par-4 colocalizes with ectopic THAP1 within PML NBs in primary endothelial cells and fibroblasts. The THAP domain is not required for Par-4 binding or PML NB localization but is essential for THAP1 proapoptotic activity. THAP1 potentiates serum withdrawal- and TNF-alpha-induced apoptosis.\",\n      \"method\": \"Co-localization (immunofluorescence), domain deletion analysis, apoptosis assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-localization and functional domain deletion in primary cells, single lab with multiple methods\",\n      \"pmids\": [\"12717420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"THAP1 regulates endothelial cell proliferation and G1/S cell-cycle progression through coordinated repression of pRB/E2F cell-cycle target genes. Chromatin immunoprecipitation showed that endogenous THAP1 associates in vivo with a consensus THAP1-binding site in the RRM1 promoter, identifying RRM1 as a direct transcriptional target. Both overexpression and RNAi silencing of THAP1 inhibited EC proliferation and downregulated pRB/E2F target genes including RRM1.\",\n      \"method\": \"Retroviral gene transfer, microarray expression profiling, RNA interference, chromatin immunoprecipitation (ChIP)\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating direct promoter occupancy plus reciprocal gain- and loss-of-function with consistent phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"17003378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"NMR structure-function analysis of the THAP zinc finger of THAP1 revealed it is an atypical zinc finger of ~80 residues with a short antiparallel beta-sheet interspersed by a loop-helix-loop insertion. Alanine scanning mutagenesis identified critical residues in the loop-helix-loop motif for DNA recognition. NMR chemical shift perturbation mapped the DNA-binding interface to a positively charged area harboring multiple lysine and arginine residues.\",\n      \"method\": \"Multidimensional NMR spectroscopy, deletion mutagenesis, alanine scanning mutagenesis, NMR chemical shift perturbation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — NMR structure determination combined with systematic mutagenesis and functional DNA-binding validation in one study\",\n      \"pmids\": [\"18073205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"A missense mutation in the THAP1 DNA-binding domain impairs DNA binding, as demonstrated by functional assay, establishing that transcriptional dysregulation via loss of THAP1 DNA-binding activity underlies DYT6 dystonia.\",\n      \"method\": \"Functional DNA-binding assay (electromobility shift or equivalent), mutation analysis\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay of DNA binding for disease mutation, single lab\",\n      \"pmids\": [\"19182804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"THAP1 associates with the transcriptional coactivator HCF-1 and O-GlcNAc transferase (OGT) in vivo. THAP1 interacts with HCF-1 through a consensus HCF-1-binding motif (HBM). ChIP assays showed that endogenous THAP1 mediates recruitment of HCF-1 to the RRM1 promoter during endothelial cell proliferation, and HCF-1 is required for transcriptional activation of RRM1.\",\n      \"method\": \"Proteomic analysis (mass spectrometry), in vitro binding assays, co-immunoprecipitation, chromatin immunoprecipitation (ChIP), RNA interference\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, MS-identified interaction, ChIP, and RNAi with functional readout; multiple orthogonal methods in one study\",\n      \"pmids\": [\"20200153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"THAP1 binds directly to the core promoter of TOR1A (DYT1) and represses its expression. Dystonia-associated mutant THAP1 shows decreased repression of TOR1A, as demonstrated by electromobility shift assays and ChIP-qPCR. Pathophysiologic mutations abolish the physical interaction between THAP1 and the TOR1A promoter.\",\n      \"method\": \"Electromobility shift assay (EMSA), chromatin immunoprecipitation (ChIP)-qPCR, luciferase reporter assays\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — EMSA and ChIP demonstrating direct promoter binding, replicated by independent group (PMID 20865765), multiple orthogonal methods\",\n      \"pmids\": [\"20976771\", \"20865765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"THAP1 forms homodimers via its C-terminal coiled-coil domain. The interaction requires residues within a 13-amino-acid region (aa 154–166) containing leucine zipper-like elements. The DYT6 frameshift mutation Q154fs180X, which eliminates most of the coiled-coil domain, abolishes self-association, whereas other tested DYT6 mutations do not prevent dimerization.\",\n      \"method\": \"Co-immunoprecipitation, yeast two-hybrid (implied by domain mapping), deletion and truncation analysis\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP-based dimerization mapping with multiple deletion constructs, single lab\",\n      \"pmids\": [\"21752024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A truncating THAP1 mutation (Asp191Thrfs*9) disrupts nuclear import, altering subcellular localization from nucleus to cytoplasm as shown by immunofluorescence microscopy of transfected cells.\",\n      \"method\": \"Immunofluorescence microscopy of transfected cells, luciferase reporter assay\",\n      \"journal\": \"European journal of human genetics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single co-localization experiment in transfected cells, single lab, limited functional follow-up\",\n      \"pmids\": [\"21847143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NMR, fluorescence, DSF, and ITC analyses of DYT6 missense mutations in the THAP domain showed that none completely abolish DNA binding; some mutations even bind DNA more strongly than wild-type. However, several mutations decrease protein thermostability, with unfolding temperatures dropping from 46°C (wild-type) to below 37°C for mutations affecting zinc coordination, the hydrophobic core, or the C-terminal AVPTIF motif, suggesting that reduced population of folded protein under physiological conditions may account for disease.\",\n      \"method\": \"NMR spectroscopy, fluorescence spectroscopy, differential scanning fluorimetry (DSF), isothermal titration calorimetry (ITC)\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — four orthogonal biophysical methods applied to multiple mutations in one study, rigorous quantitative assessment\",\n      \"pmids\": [\"22844099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Truncated THAP1 mutations (F22fs71X and F25fs53X) alter subcellular localization to both cytoplasm and nucleus, whereas missense mutations (C54F and L180S) remain predominantly nuclear, as shown by immunofluorescence and Western blot in transfected HEK-293T cells.\",\n      \"method\": \"Immunofluorescence microscopy, Western blot, transfection in HEK-293T cells\",\n      \"journal\": \"Parkinsonism & related disorders\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, overexpression in non-neuronal cell line, no functional consequence directly tested\",\n      \"pmids\": [\"22652465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"THAP1 autoregulates its own expression by binding to the THAP1 minimal promoter (a 480-bp fragment) and repressing transcription. This was demonstrated by luciferase reporter assays and quantitative ChIP. DYT6-causing mutations disrupt this autoregulation. Overexpressed THAP1 is preferentially degraded via the proteasome, and endogenous THAP1 levels are reduced in cells overexpressing wild-type THAP1.\",\n      \"method\": \"Luciferase reporter assay, quantitative ChIP, RT-qPCR, proteasome inhibitor treatment\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus reporter assay plus endogenous expression measurement, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"25088175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Endogenous THAP1 exists as multiple protein species (29–30 kDa, 32 kDa, 47 kDa, and 50–52 kDa) in neurons. The 50-kDa species is exclusively detected in murine brain and testes and is localized to the nuclear compartment, distinct from non-neuronal isoforms, suggesting neuron-specific post-translational modifications.\",\n      \"method\": \"Western blotting, immunoprecipitation, DNA oligonucleotide affinity chromatography, subcellular fractionation\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple antibodies validated by IP and affinity chromatography, in vivo tissue fractionation, single lab\",\n      \"pmids\": [\"25231164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"THAP1 is essential for timing the initiation of CNS myelination in a cell-autonomous manner within the oligodendrocyte (OL) lineage. Conditional deletion of THAP1 in the CNS retards OL maturation, delays myelination, and causes persistent motor deficits. Loss of THAP1 disrupts a core set of OL maturation genes and reduces DNA occupancy of YY1, a transcription factor required for OL maturation.\",\n      \"method\": \"Conditional knockout mouse (CNS-specific Cre), OL progenitor purification and developmental assays, ChIP, motor behavior testing\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO with defined cellular and behavioral phenotype, ChIP for mechanistic placement, in vitro OPC rescue, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"28697333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"THAP1 regulates embryonic stem cell survival, proliferation, and neuroectodermal differentiation. Loss of THAP1 or expression of a disease-causing mutation enhances cell death, prolongs pluripotency gene expression (Nanog, Prdm14, Rex1) upon differentiation, and impairs upregulation of ectodermal genes. ChIP-Seq reveals that these activities are partly due to indirect regulation of gene expression.\",\n      \"method\": \"Knockout ESCs, disease-mutation knock-in ESCs, ChIP-Seq, differentiation assays, cell survival assays\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and KI in ESCs with ChIP-Seq, single lab with multiple methods\",\n      \"pmids\": [\"28579396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The THAP1 homodimerization domain maps to amino acids 139–185 of the coiled-coil region. Yeast two-hybrid, GST pull-down, and cross-linking assays confirmed this region mediates homodimerization. Nine DYT6-causing missense mutations within this region had no effect on THAP1 dimerization.\",\n      \"method\": \"Yeast two-hybrid, GST pull-down, formaldehyde cross-linking assays\",\n      \"journal\": \"Journal of molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three orthogonal protein-interaction methods in one study, single lab\",\n      \"pmids\": [\"28299530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Heterozygous Thap1 C54Y or ΔExon2 alleles in mouse striatum and cerebellum dysregulate pathways including eIF2α signaling, mitochondrial dysfunction, neuron projection development, axonal guidance signaling, and synaptic long-term depression in a genotype- and tissue-dependent manner. There is a unique neuronal 50-kDa Thap1 immunoreactive species, and Thap1 levels are auto-regulated at the mRNA level. Electrophysiological and neurite outgrowth deficits consistent with pathway enrichments were partially corrected by salubrinal.\",\n      \"method\": \"RNA-Seq (in vivo), electrophysiology, neurite outgrowth assays, pharmacological rescue\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo RNA-Seq with functional electrophysiological and pharmacological validation, single lab\",\n      \"pmids\": [\"29364887\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"THAP1, together with YY1 and HCF1, binds directly to the SHLD1 promoter and cooperatively maintains low basal expression of the Shieldin component SHLD1, thereby regulating the choice between end protection and resection during DNA double-strand break repair. Loss of THAP1-dependent SHLD1 expression confers cross-resistance to PARP inhibitors and cisplatin in BRCA1-deficient cells.\",\n      \"method\": \"ChIP, promoter reporter assays, PARP inhibitor sensitivity assays, genetic rescue experiments in BRCA1-deficient cells\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct ChIP of promoter binding, functional genetic rescue, multiple cell-line and mouse model validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33857404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"THAP1 modulates oligodendrocyte maturation by regulating lysosomal glycosaminoglycan (GAG) catabolism in OPCs. Thap1-null OPCs accumulate and secrete excess GAGs, inhibiting their maturation via an autoinhibitory mechanism. THAP1 binds to and regulates the GusB gene encoding β-glucuronidase. Applying GAG-degrading enzymes or overexpressing β-glucuronidase rescues Thap1-null OL maturation deficits in vitro and in vivo.\",\n      \"method\": \"Thap1 knockout OPCs, ChIP (GusB promoter binding), glycosaminoglycan quantification, rescue by GAG-degrading enzymes and GusB overexpression in vitro and in vivo\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating direct target gene binding, biochemical GAG measurement, and in vivo rescue experiment; multiple orthogonal methods, single lab\",\n      \"pmids\": [\"34312226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Dystonia-specific THAP1 mutations dysregulate genes related to neurodevelopment, lysosomal lipid metabolism, and myelin in near-isogenic iPSC-derived neural stem cells. In vivo, Thap1-disruptive alleles in mice cause significant changes in myelin gene expression and reduction of myelin structural integrity.\",\n      \"method\": \"iPSC-derived neural stem cells (allelic series of 8 mutations), RNA-Seq, mouse myelin histology/gene expression\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — near-isogenic iPSC allelic series (n=94 lines) plus in vivo mouse confirmation, multiple mutations and methods\",\n      \"pmids\": [\"34672987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The DYT6 missense mutation F81L (THAP1F81L) impairs THAP1 transcriptional activity and disrupts CNS myelination. THAP1F81L exhibits normal DNA binding but causes significantly reduced DNA binding of its transcriptional partner YY1 at target promoters, suggesting the mutation disrupts formation of an active transcription complex rather than direct DNA binding.\",\n      \"method\": \"Knock-in mouse model, ChIP (YY1 and THAP1 occupancy), myelination assays, transcriptional reporter assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knock-in mouse with ChIP demonstrating mechanism (YY1 displacement), in vivo myelination phenotype, multiple methods in single study\",\n      \"pmids\": [\"34686877\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"THAP1 regulates gene expression mainly through control of SP1 family members SP1 and SP4 in a cell-type-dependent manner. ChIP-seq showed THAP1 directly targets only a minority of differentially expressed genes; the majority are regulated indirectly via SP1/SP4. Common dysregulated genes across THAP1 patient neurons and knockout rat striatum involve synaptic transmission, nervous system development, and locomotor behavior pathways.\",\n      \"method\": \"ChIP-seq, RNA-seq, transcriptomic comparison across multiple model systems (patient iPSC-derived neurons, KO rat striatum, patient frontal cortex), electrophysiology, behavioral assays\",\n      \"journal\": \"Brain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP-seq with multiple independent model systems and functional electrophysiological/behavioral validation\",\n      \"pmids\": [\"35015830\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Par-4 and THAP1 form a protein complex via interaction of their carboxyl termini, and this complex binds to the CCAR1 promoter through the zinc-dependent DNA-binding domain of THAP1 at its amino terminus. The Par-4/THAP1 complex and Notch3 competitively bind to the CCAR1 promoter and antagonistically regulate alternative pre-mRNA splicing of CCAR1 via splicing factors SRp40 and SRp55, determining T-ALL cell survival.\",\n      \"method\": \"Co-immunoprecipitation, luciferase reporter assay, ChIP, alternative splicing analysis\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of complex, ChIP of promoter binding, splicing assays; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"23975424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"THAP1 directly binds the promoter of the SOD2 (superoxide dismutase 2) gene as shown by ChIP-seq, and overexpression of THAP1 in SK-N-AS cells increases SOD2 protein expression, whereas fibroblasts from THAP1 patients show reduced SOD2 expression. Disease mutations C54Y and F81L decrease THAP1 protein stability.\",\n      \"method\": \"ChIP-seq, microarray expression profiling, Western blot, patient fibroblast analysis\",\n      \"journal\": \"Journal of molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP-seq for direct binding plus gain- and loss-of-function expression data; single lab\",\n      \"pmids\": [\"32112337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"THAP1 directly regulates the expression of PSMB5, which encodes the central protease subunit β5 of the 26S proteasome. Depletion of THAP1 disrupts proteasome assembly, reduces proteasome activity, and leads to accumulation of ubiquitinated proteins and cell death. This was identified through a genome-wide genetic screen and confirmed by direct PSMB5 promoter binding and rescue experiments.\",\n      \"method\": \"Genome-wide genetic screen (DepMap coessentiality), THAP1 depletion, proteasome activity assays, ubiquitinated protein accumulation assay, PSMB5 promoter binding assays, RNA-seq, deep mutational scanning of THAP1\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — two independent publications (PMIDs 39952963 and 39929834) with genome-wide screen, direct promoter binding, proteasome assembly and activity assays, and deep mutational scan\",\n      \"pmids\": [\"39952963\", \"39929834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"THAP1 functions as a maternal effect factor in mouse oocytes and early embryos. Oocyte-specific deletion of Thap1 causes 1-2-cell arrest, defective zygotic genome activation, and impaired female fertility. Mechanistically, THAP1 activates Rrm1 (ribonucleotide reductase) in oocytes to generate dNTPs; overexpression of Rrm1 in Thap1 maternal-KO zygotes nearly fully rescues 2-cell progression and ZGA.\",\n      \"method\": \"Oocyte-specific conditional knockout, low-input metabolomics, RNA-seq (ZGA assay), Rrm1 mRNA rescue by overexpression\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with direct genetic rescue by Rrm1 overexpression, metabolomics confirming dNTP depletion, multiple orthogonal methods in one study\",\n      \"pmids\": [\"41731150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Loss of THAP1 in striatal medium spiny neurons derived from DYT-THAP1 patient iPSCs results in significantly lower GABA-evoked calcium amplitudes and marked downregulation of the GABA-A receptor alpha2 subunit gene, lower frequency of miniature postsynaptic currents, and elevated spontaneous action potential frequency, indicating decreased GABAergic transmission and neuronal disinhibition/hyperexcitability.\",\n      \"method\": \"iPSC-derived medium spiny neurons, calcium imaging, qPCR, whole-cell patch-clamp electrophysiology\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — patient iPSC-derived neurons with electrophysiology and molecular quantification, single lab\",\n      \"pmids\": [\"34095114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Conditional deletion of Thap1 in neural/glial precursors (nestin-Cre) causes pronounced locomotor deficits with transcriptional changes in genes involved in nervous system development, synaptic transmission, cytoskeleton, gliosis, and dopamine signaling. Germline deletion of Thap1 is embryonic lethal. Heterozygous mice show autoregulation of Thap1 mRNA with compensatory upregulation from the intact allele.\",\n      \"method\": \"Conditional knockout mice (nestin-Cre), germline knockout, RNA-seq, behavioral testing\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo conditional KO with behavioral and transcriptomic phenotyping, single lab\",\n      \"pmids\": [\"30590536\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"THAP1 is a zinc-dependent, sequence-specific DNA-binding transcription factor (via its N-terminal THAP zinc finger domain) that recruits the coactivator HCF-1 and OGT to target promoters including RRM1, TOR1A, SOD2, PSMB5, and GusB; it represses TOR1A and its own promoter (autoregulation), activates RRM1 and PSMB5 (maintaining proteasome function), and in partnership with YY1 controls myelination by regulating OL lineage maturation through lysosomal GAG catabolism; THAP1 also interacts with Par-4 at PML nuclear bodies to promote apoptosis, homodimerizes via a leucine zipper-like coiled-coil (aa 154–166), and binds the SHLD1 promoter together with YY1 and HCF1 to balance DNA double-strand break repair pathway choice, with DYT6-causing mutations impairing DNA binding, protein stability, autoregulation, YY1 co-recruitment, or nuclear localization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"THAP1 is a zinc-dependent, sequence-specific DNA-binding transcription factor that controls cell proliferation, differentiation, and survival through direct occupancy of defined promoter elements [#0, #2]. DNA recognition is mediated by an N-terminal atypical THAP zinc finger of ~80 residues that folds as an antiparallel beta-sheet with a loop-helix-loop insertion contacting an 11-nucleotide consensus, and that requires both zinc coordination through its C2CH motif and a positively charged lysine/arginine surface [#0, #3]. THAP1 acts within multiprotein transcriptional complexes: it recruits the coactivator HCF-1 (and associated OGT) to the RRM1 promoter to drive pRB/E2F-dependent cell-cycle gene expression and endothelial proliferation [#2, #5], represses the dystonia gene TOR1A and autoregulates its own promoter [#6, #11], and activates SOD2 and the proteasome subunit gene PSMB5 — the latter sustaining proteasome assembly and clearance of ubiquitinated proteins [#23, #24]. Much of its transcriptional output is indirect, channeled through control of the SP1/SP4 family in a cell-type-dependent manner [#21]. In the oligodendrocyte lineage THAP1 partners with YY1 to time CNS myelination cell-autonomously, in part by regulating lysosomal glycosaminoglycan catabolism via the β-glucuronidase gene GusB [#13, #18, #20]. THAP1 also balances DNA double-strand break repair pathway choice by binding the SHLD1 promoter together with YY1 and HCF1 to restrain Shieldin expression [#17], drives apoptosis through interaction with Par-4 at PML nuclear bodies and at the CCAR1 promoter [#1, #22], and acts as a maternal-effect factor activating Rrm1 to supply dNTPs for zygotic genome activation [#25]. The protein homodimerizes through a C-terminal coiled-coil region (aa 139–185) [#7, #15]. Dominant DYT6 dystonia is caused by THAP1 mutations that act through heterogeneous mechanisms — impaired DNA binding, reduced protein thermostability, loss of autoregulation, disrupted YY1 co-recruitment, or defective nuclear import — converging on transcriptional dysregulation [#4, #9, #11, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established THAP1's first cellular role by showing it is a nuclear proapoptotic factor, placing it in PML nuclear bodies and physically linked to Par-4 before any DNA-binding function was known.\",\n      \"evidence\": \"Co-localization, domain-deletion analysis, and apoptosis assays in primary endothelial cells and fibroblasts\",\n      \"pmids\": [\"12717420\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify direct transcriptional targets\", \"THAP domain shown dispensable for Par-4 binding but required for apoptosis without mechanism\", \"Single lab co-localization\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined the molecular activity of THAP1 by demonstrating the THAP domain is a zinc-dependent sequence-specific DNA-binding module with an 11-nucleotide consensus, converting an apoptosis factor into a candidate transcription factor.\",\n      \"evidence\": \"In vitro binding-site selection, zinc chelation, and site-directed mutagenesis\",\n      \"pmids\": [\"15863623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No in vivo target gene identified\", \"No structural model of domain\", \"Did not address transcriptional activation versus repression\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected DNA binding to physiological output by identifying RRM1 as a direct in vivo target and placing THAP1 in pRB/E2F-dependent control of G1/S progression and endothelial proliferation.\",\n      \"evidence\": \"ChIP for promoter occupancy plus reciprocal overexpression and RNAi with proliferation readout\",\n      \"pmids\": [\"17003378\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify coactivators recruited\", \"Mechanism of pRB/E2F target regulation indirect\", \"Restricted to endothelial cells\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Resolved how THAP1 recognizes DNA by determining the NMR structure of the atypical zinc finger and mapping the loop-helix-loop DNA-binding interface.\",\n      \"evidence\": \"Multidimensional NMR, alanine scanning, and chemical shift perturbation\",\n      \"pmids\": [\"18073205\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-structure with DNA\", \"C-terminal coiled-coil not structurally characterized\", \"Did not address full-length protein behavior\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Provided the first disease mechanism by showing a DYT6 missense mutation in the DNA-binding domain abolishes DNA binding, framing dystonia as transcriptional dysregulation.\",\n      \"evidence\": \"Functional DNA-binding assay of a disease mutation\",\n      \"pmids\": [\"19182804\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single mutation tested\", \"Did not establish which target genes are affected\", \"No in vivo confirmation\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified the coactivator machinery THAP1 uses and a key repressed target, showing THAP1 recruits HCF-1/OGT to activate RRM1 and directly represses the dystonia gene TOR1A.\",\n      \"evidence\": \"Mass spectrometry, reciprocal co-IP, ChIP, and RNAi (HCF-1/OGT); EMSA, ChIP-qPCR, and luciferase reporters (TOR1A), with independent replication\",\n      \"pmids\": [\"20200153\", \"20976771\", \"20865765\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How activation versus repression is determined at different promoters unresolved\", \"OGT functional contribution not dissected\", \"Link between TOR1A repression and dystonia phenotype not tested in vivo\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Showed THAP1 homodimerizes through a C-terminal coiled-coil, and that a frameshift removing this region abolishes self-association while subcellular mislocalization defines another mutation class.\",\n      \"evidence\": \"Co-IP and deletion mapping (dimerization); immunofluorescence of transfected cells (mislocalization)\",\n      \"pmids\": [\"21752024\", \"21847143\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of dimerization for transcription not established\", \"Mislocalization shown in overexpression only\", \"Most DYT6 mutations do not affect dimerization, leaving their mechanism open\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Reframed DYT6 pathogenesis by showing most THAP-domain missense mutations do not abolish DNA binding but instead destabilize the folded protein below physiological temperature.\",\n      \"evidence\": \"NMR, fluorescence, differential scanning fluorimetry, and ITC across multiple mutations; immunofluorescence localization of truncations\",\n      \"pmids\": [\"22844099\", \"22652465\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Thermostability measured in vitro, not in cells\", \"Did not test whether destabilized protein is degraded in vivo\", \"Localization data from overexpression in non-neuronal cells\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Extended the Par-4 partnership into transcriptional and splicing control, showing the Par-4/THAP1 complex binds the CCAR1 promoter and antagonizes Notch3 to govern alternative splicing and T-ALL survival.\",\n      \"evidence\": \"Co-IP, ChIP, luciferase reporter, and splicing analysis\",\n      \"pmids\": [\"23975424\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Splicing regulation mechanism via SRp40/SRp55 not fully resolved\", \"Single cancer-cell context\", \"Relationship to canonical THAP1 transcriptional targets unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established negative autoregulation and protein turnover as control mechanisms, showing THAP1 represses its own promoter, is degraded by the proteasome, and exists as neuron-specific protein species.\",\n      \"evidence\": \"Luciferase reporters, quantitative ChIP, RT-qPCR, and proteasome inhibition; Western blot, IP, and subcellular fractionation across tissues\",\n      \"pmids\": [\"25088175\", \"25231164\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of neuron-specific post-translational modifications unknown\", \"Ubiquitin ligase mediating degradation not identified\", \"Functional role of distinct isoforms untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined THAP1's developmental functions in vivo, showing it is required cell-autonomously for oligodendrocyte maturation and myelination timing via YY1, and for embryonic stem cell survival and neuroectodermal differentiation.\",\n      \"evidence\": \"Conditional knockout mice with OL purification and ChIP (myelination); knockout/knock-in ESCs with ChIP-Seq (differentiation)\",\n      \"pmids\": [\"28697333\", \"28579396\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect target genes not fully separated\", \"Mechanism of YY1 co-occupancy unresolved at this stage\", \"Link to dystonia phenotype not yet established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked THAP1 dysfunction to specific neuronal pathways in vivo, showing heterozygous dystonia alleles dysregulate eIF2α signaling and synaptic pathways with electrophysiological deficits partially rescued pharmacologically.\",\n      \"evidence\": \"In vivo RNA-Seq of mouse striatum/cerebellum, electrophysiology, neurite outgrowth, and salubrinal rescue\",\n      \"pmids\": [\"29364887\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct THAP1 targets among dysregulated genes not defined\", \"Tissue- and genotype-dependent effects mechanistically unexplained\", \"salubrinal rescue only partial\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Added oxidative-stress defense to THAP1's regulon by showing direct SOD2 promoter binding with dose-dependent expression control, and reinforced that disease mutations reduce protein stability.\",\n      \"evidence\": \"ChIP-seq, expression profiling, Western blot, and patient fibroblast analysis\",\n      \"pmids\": [\"32112337\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological consequence of altered SOD2 not tested\", \"Single lab\", \"Cofactor requirements at SOD2 promoter unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Diversified THAP1's mechanistic repertoire across DNA repair, myelination metabolism, neuronal excitability, and SP1/SP4-mediated gene control, while resolving that most THAP1 transcriptional output is indirect.\",\n      \"evidence\": \"ChIP and PARP-inhibitor genetics (SHLD1); knockout OPCs with ChIP and GAG/GusB rescue; patient iPSC neurons with patch-clamp; iPSC allelic series with RNA-Seq and mouse myelin histology; ChIP-seq/RNA-seq across multiple models (SP1/SP4)\",\n      \"pmids\": [\"33857404\", \"34312226\", \"34672987\", \"34095114\", \"35015830\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How a single factor selects among repair, metabolic, and neuronal programs unclear\", \"Determinants of direct versus SP1/SP4-indirect regulation undefined\", \"Causal chain from transcriptional changes to dystonia behavior incomplete\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a transcription-complex-assembly mechanism for disease by showing the DYT6 F81L mutant binds DNA normally yet fails to co-recruit YY1, disrupting myelination.\",\n      \"evidence\": \"Knock-in mouse with ChIP for THAP1 and YY1 occupancy, myelination and reporter assays\",\n      \"pmids\": [\"34686877\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of THAP1–YY1 cooperativity unknown\", \"Whether other DYT6 mutations share this mechanism not tested here\", \"Direct biochemical THAP1–YY1 interaction not demonstrated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Revealed an essential proteostasis function, showing THAP1 directly drives PSMB5 expression to sustain proteasome assembly and prevent toxic ubiquitinated-protein accumulation.\",\n      \"evidence\": \"Genome-wide coessentiality screen, depletion with proteasome activity assays, PSMB5 promoter binding, and deep mutational scanning, across two independent reports\",\n      \"pmids\": [\"39952963\", \"39929834\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue specificity of proteasome dependence unexplored\", \"Relationship between proteasome control and dystonia phenotypes unknown\", \"Cofactors at PSMB5 promoter not defined\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identified a maternal-effect role, showing oocyte THAP1 activates Rrm1 to supply dNTPs required for zygotic genome activation and early embryonic progression.\",\n      \"evidence\": \"Oocyte-specific conditional knockout, low-input metabolomics, RNA-seq, and Rrm1 mRNA rescue\",\n      \"pmids\": [\"41731150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RRM1 control is conserved in somatic THAP1 functions not addressed\", \"Other maternal targets not mapped\", \"Link to human reproductive phenotypes unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How THAP1 selects among its diverse promoter targets and decides between activation and repression, direct versus SP1/SP4-mediated control, and which cofactor (HCF-1, YY1, Par-4, OGT) is engaged in a given cellular context remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unifying model linking context to cofactor choice\", \"Causal chain from specific transcriptional changes to DYT6 dystonia incomplete\", \"Genome-wide direct binding versus functional output discordance unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 3, 6, 17, 18, 23, 24]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 5, 6, 11, 21, 24]},\n      {\"term_id\": \"GO:0003700\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 8, 10, 12]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [1, 2, 5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 5, 6, 11, 21]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [2, 25]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [17]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [13, 14, 18, 20]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [24]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [1, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"HCF1\", \"OGT\", \"YY1\", \"PAWR\", \"SP1\", \"SP4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}